Is phosphoadenosine phosphate phosphatase a target of lithium’s therapeutic effect?

@article{Shaltiel2009IsPP,
  title={Is phosphoadenosine phosphate phosphatase a target of lithium’s therapeutic effect?},
  author={Galit Shaltiel and Joseph Deutsch and Stanley I. Rapoport and Mireille Basselin and Robert Haim Belmaker and Galila Agam},
  journal={Journal of Neural Transmission},
  year={2009},
  volume={116},
  pages={1543-1549}
}
Lithium, which is approved for treating patients with bipolar disorder, is reported to inhibit 3′(2′)-phosphoadenosine-5′-phosphate (PAP) phosphatase activity. In yeast, deletion of PAP phosphatase results in elevated PAP levels and in inhibition of sulfation and of growth. The effect of lithium on PAP phosphatase is remarkable for the low Ki (~0.2 mM), suggesting that this system would be almost completely shut down in vivo with therapeutic levels of 1 mM lithium, thereby elevating PAP levels… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Similar Papers

Loading similar papers…